The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from post-allergen peak)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The Magnitude of the Early Asthmatic Response, Expressed as a Percentage Change in FEV1.
Timeframe: Before inhalation 3 hours
The Magnitude of the Late Asthmatic Response, Expressed as a Percentage Change in FEV1.
Timeframe: 7 hours after challenge